Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Other Non-Current Liabilities (2016 - 2026)

Angiodynamics' Other Non-Current Liabilities history spans 15 years, with the latest figure at $16.7 million for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities fell 3.86% year-over-year to $16.7 million; the TTM value through Feb 2026 reached $16.7 million, down 3.86%, while the annual FY2025 figure was $16.9 million, 5.14% up from the prior year.
  • Other Non-Current Liabilities reached $16.7 million in Q1 2026 per ANGO's latest filing, down from $17.1 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $17.4 million in Q1 2025 to a low of $2.6 million in Q4 2023.
  • Average Other Non-Current Liabilities over 5 years is $11.2 million, with a median of $14.2 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 81.58% in 2023, then skyrocketed 428.26% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $3.5 million in 2022, then decreased by 26.16% to $2.6 million in 2023, then soared by 355.53% to $11.9 million in 2024, then skyrocketed by 43.88% to $17.1 million in 2025, then fell by 2.07% to $16.7 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Other Non-Current Liabilities are $16.7 million (Q1 2026), $17.1 million (Q4 2025), and $14.2 million (Q3 2025).